Opendata, web and dolomites


Rational Design and Construction of Viral Based Products

Total Cost €


EC-Contrib. €






Project "SynVaccine" data sheet

The following table provides information about the project.


Organization address
address: HABARZEL ST 27
city: TEL AVIV
postcode: 6971039
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2017-09-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SYNVACCINE LTD IL (TEL AVIV) coordinator 50˙000.00


 Project objective

In order to be fully effective as an oncolytic virus or vaccine, achieving of precise and specific traits are pivotal. However, current technologies are limited to the confines of a virus’s existing biological make-up.

They are left with manipulation of genes within the virus e.g. deleting and adding proteins, inability to manipulate silent codes etc. where achievement of such precision is simply not possible from such naturally-rooted manipulation.

The SynVaccine solution taps into 3 billion years of viral evolutionary data which is continually updated, ensuring the highest degree of accuracy on rules that govern all viruses found today. Through this, it becomes the only solution to govern the rules of viruses on a cellular level, giving the important ability to precisely dictate the traits and behaviour of the newly designed, bottom-up, created viruses.

As a result, only the most effective oncolytic viruses and vaccines are ever produced, ensuring the highest levels of treatment and immunity.

We have invested over €3.1 million into the development and testing of our solution to ensure its robustness and efficiency, and thus move into the next stage of specific drug development. Our management and scientific leadership capacity involves 10 multi-disciplinary experts in the fields of; entrepreneurship, virology, synthetic biology, computational biology, engineering and automation.

The proposed work in Phase 1 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of our SynVaccine derived solutions, and their market uptake.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SYNVACCINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SYNVACCINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  


Laser-spectroscopic sensing device for diagnostic assessment of sinusitis

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More